2022 news preview: Expect a row over controversial Alzheimer’s drug
By Clare Wilson A participant in a clinical trial for aducanumab Kayana Szymczak/New York Times/Redux/eyevine EXPECT to see debate over a new medicine to treat Alzheimer’s disease, called aducanumab, continue into 2022. Approved in the US last June, it is the first drug designed to treat a possible cause of this form of dementia, rather than the symptoms. … Read more